Member Login
Search

LUGPA Policy Update – Trump Administration Announces Tariffs on Imported Patented Pharmaceuticals

May 2026

At-a-Glance Essentials

  • What’s Changing: 100% tariff on imported patented pharmaceuticals and Active Pharmaceutical Ingredients (APIs) under Section 232 national security authority. Tiered reductions and broad exemptions apply.
  • Why It Matters: Potential cost increases for certain patented urologic therapies (especially oncology/specialty drugs), but limited impact on generics/biosimilars.
  • Action Points: Monitor supplier pricing, in-office dispensing, and specialty pharmacy operations. Track product-specific exemptions.

Key Timelines

  • July 31, 2026 (120 days): Large manufacturers
  • September 29, 2026 (180 days): Small/midsize companies
  • January 20, 2029: MFN exemption expiration for select firms

Background

On April 2, 2026, the White House issued a proclamation under Section 232 of the Trade Expansion Act of 1962 following a Department of Commerce investigation. The report highlighted U.S. vulnerability due to heavy reliance on foreign manufacturing; only about 15% of patented APIs are produced domestically. The policy aims to strengthen national security, reduce supply chain risks, and incentivize the onshoring of pharmaceutical production.

Key Provisions

  • Base Tariff: 100% on imported patented drugs/APIs
  • Reduced Rates: 15% for select trade partners (EU, Japan, Korea, Switzerland, Liechtenstein); 20% for companies committing to U.S. onshoring
  • Exemptions: Full for generics, biosimilars, and many orphan/specialty drugs; UK under new agreement; temporary MFN pricing exemptions for certain large manufacturers

Implications for Independent Urology

  • Cost Pressures: Possible increases for patented prostate/bladder cancer therapies and other specialty drugs without exemptions.
  • Limited Disruption: Most common urologic generics (BPH, OAB, infections) are fully exempt.
  • Operations: In-office dispensing and specialty pharmacies should watch for pricing/availability changes.
  • Long-Term: Expected to accelerate U.S. manufacturing and improve supply chain resilience.

LUGPA Position

LUGPA supports stronger domestic manufacturing and supply chain security but will advocate to protect patient access and minimize cost increases or disruptions in urologic care. We will continue monitoring implementation and provide member updates.